Longeveron Inc. - Class A Common stock (NQ:LGVN)

BioMedNewsBreaks — Longeveron Inc. (NASDAQ: LGVN; LGVNR) Study Survival Data Reported at AHA’s 2023 Scientific Sessions

November 13, 2023

BioMedNewsBreaks – Longeveron Inc. (NASDAQ: LGVN) Announces 2023 Results, Provides Corporate Update

November 10, 2023

Sex Hormones Could Influence Alzheimer’s Development, Researchers Say

November 06, 2023

BioMedNewsBreaks — Longeveron Inc. (NASDAQ: LGVN; LGVNR) Announces Plans to Release Q3 2023 Financial Report, Host Corporate Update Call

November 03, 2023

Longeveron Inc. (NASDAQ: LGVN) Validates Safety and Therapeutic Potential of its Lomecel-B(TM) Lead Investigational Product in its CLEAR MIND Phase 2a Clinical Trial

October 30, 2023

BioMedNewsBreaks — Longeveron Inc. (NASDAQ: LGVN; LGVNR) Top-Line Results from Phase 2a Trial Spotlighted in Latest NNA Release

October 24, 2023

BioMedNewsBreaks — Longeveron Inc. (NASDAQ: LGVN; LGVNR) Closes on $4M Registered Direct Offering

October 16, 2023

BioMedNewsBreaks — Longeveron Inc. (NASDAQ: LGVN; LGVNR) Enters into $4M Registered Direct Offering

October 12, 2023

BioMedNewsBreaks — Longeveron Inc. (NASDAQ: LGVN; LGVNR) Reports Top-Line Results for Phase 2a Lomecel-B Clinical Trial

October 05, 2023

Longeveron Inc. (NASDAQ: LGVN) Eyeing Global HLHS, in addition to Alzheimer’s Disease, and Aging-Related Frailty Treatment Markets with Lomecel-B(TM), its Lead Investigational Product

September 27, 2023

Longeveron Inc. (NASDAQ: LGVN) to Discuss Its Cellular Therapy Programs, Clinical Trial Progress at the 25th Annual H.C. Wainwright Global Investment Conference

September 14, 2023

Longeveron (NASDAQ: LGVN) Reports 100% 5-Year Survival In Trial For Rare Pediatric Disease HLHS (Compared To 80% Survival In Historical Trials) To Market

September 12, 2023

BioMedNewsBreaks — Longeveron Inc. (NASDAQ: LGVN; LGVNR) CEO Releases Stockholder Letter

September 11, 2023

Longeveron Inc. (NASDAQ: LGVN) Is ‘One to Watch’

September 08, 2023

BioMedNewsBreaks — Longeveron Inc. (NASDAQ: LGVN; LGVNR) Announces ELPIS 1 Trial Data Accepted for AHA Presentation, IBN Partnership

September 07, 2023

Upcoming Phase 2 Data Expected For Longeveron’s (NASDAQ: LGVN) Drug For the $4+ Billion Alzheimer’s Sector – What To Look For

September 07, 2023

BioMedNewsBreaks – Longeveron Inc. (NASDAQ: LGVN) to Present at Upcoming H.C. Wainwright Global Investment Conference

September 05, 2023

BioMedNewsBreaks — Longeveron Inc. (NASDAQ: LGVN; LGVNR) Announces Participation at Upcoming National Investment Banking Association Conference

August 30, 2023

Longeveron Announces Key Additions To Its Leadership Team and Board As It Gears Up For Phase 2 Trials For Its Lead Drug Candidate For Several Conditions

August 08, 2023

HLHS Is A Rare And Serious Congenital Heart Disease With A 33% Neonatal Death Rate — Could Longeveron’s Lomecel-B Improve Outcomes?

July 07, 2023

Palm Beach, FL – April 13, 2022 – FinancialNewsMedia.com News Commentary – Dementia is the loss of cognitive functioning, thinking, remembering, reasoning, and behavioral abilities to such an extent...

Exposures Product Safety

Cognitive Drugs Market Expected Reach Revenues Of $21 Billion in 2027

April 13, 2022

Palm Beach, FL – March 31, 2022 – FinancialNewsMedia.com News Commentary – Alzheimer’s disease (AD) is an irreversible, progressive neurodegenerative disease. It is the most common cause of dementia...

Exposures COVID-19

R&D Efforts for Alzheimer’s Therapies on the Rise with over 120 Drugs in Development

March 31, 2022

Longeveron Inc. (NASDAQ:LGVN) Long Term Investor Notice: Investigation of Potential Wrongdoing

December 17, 2021

San Diego, CA -- (SBWIRE) -- 12/17/2021 -- An investigation on behalf of current long-term investors in shares of Longeveron Inc. (NASDAQ:LGVN) concerning potential breaches of fiduciary duties by...

Via SBWire

FINAL DEADLINE ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Longeveron Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

November 12, 2021

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Via NewMediaWire

Topics Initial Public Offering Lawsuit

Exposures Financial Legal Securities Market

Alzheimer’s Disease Expected to Triple by 2050 While the Development Process for Potential Drug Candidates Increases

January 05, 2022

Palm Beach, FL – January 5, 2022 – FinancialNewsMedia.com News Commentary – Alzheimer’s disease (AD) is the most common reason of progressive dementia in the elderly population. There has been an...

DEADLINE FRIDAY REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Longeveron Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

Topics Death

Exposures Death

November 10, 2021

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Via NewMediaWire

Topics Initial Public Offering Lawsuit

Exposures Financial Legal Securities Market

Systemic Mastocytosis Treatments Gain Hope Due To Increasing Novel Treatment Options

December 21, 2021

Palm Beach, FL –December 21, 2021 – FinancialNewsMedia.com News Commentary – Systemic mastocytosis is rare disease which affects very few people and it causes due to C-kit mutation which leads to...

Palm Beach, FL –December 8, 2021 – FinancialNewsMedia.com News Commentary – Systemic Lupus Erythematosus is also known as lupus. It is an autoimmune disease that affects all parts of your body. The...

Exposures Product Safety

Systemic Lupus Erythematosus Treatment Market Projected To Reach $3.56 Billion By 2027

December 08, 2021

Increased Prevalence of Atopic Dermatitis Fueling Impressive Growth for Atopic Dermatitis Drugs

November 30, 2021

Palm Beach, FL –November 30, 2021 – FinancialNewsMedia.com News Commentary – Atopic dermatitis is a chronic inflammatory skin condition characterized by red, itchy, swollen, and broken skin. White...